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In this issue of the Journal, Driessen-Mol et al. (1) from
Zurich present their latest work in a long series of in-
vestigations into the feasibility of tissue-engineered heart
valves. The Zurich tissue engineering heart valve program
dates back over a decade with pioneering work with stem
cell–based therapy using vascular-derived differentiated cells,
mesenchymal stem/progenitor cells, blood-derived stem
cells, and placental stem cells. The authors have previously
demonstrated proof of concept of creating an autologous,
living heart valve prosthesis using tissue-engineered tech-
nologies with regeneration and repair capacities (2). MoreSee page 1320recently, the authors have focused their work on combining
stem cell–based tissue-engineered heart valves with a
transcatheter aortic valve replacement (TAVR) approach for
delivery (3). The ultimate goal of their research is to produce
an autologous, living heart valve prosthesis with regenerative
and repair capability delivered by a catheter-based approach.
Indeed, the authors have demonstrated the feasibility of this
concept in previously published work (4). Although the
authors were successful in demonstrating this concept suc-
cessfully in the animal model, they foresaw some signiﬁcant
limitations for the clinical applicability of tissue-engineered
autologous heart valves in the human due to timing, logis-
tical, and expense issues. The need for cell harvest, scaffold
seeding, and bioreactor culture for this approach were suf-
ﬁciently substantial that they felt that clinical application was
not realistic.
Therefore, they felt that a homologous tissue-engineered
transcatheter valve that would be available “off the shelf,” as
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reality. To accomplish this, they performed a series of ex-
periments in the sheep model in which homologous tissue
engineered transcatheter heart valves were implanted in the
pulmonary position by a transapical approach. They used a
synthetic scaffold that rapidly dissolves populated by
vascular-derived cells and then decellularized. They were
able to demonstrate functionality of the valve and matrix
remodeling that corresponded to the rate of host cell re-
population of the scaffold. Although immediate valve func-
tion was excellent, compromised leaﬂet coaptation occurred
by 24 weeks. Nonetheless, the concept of a tissue-engineered
heart valve with rapid cellular repopulation, tissue remodel-
ing, and self-repair capability has been demonstrated.
On the basis of this proof of concept in the pre-clinical
model, it is therefore appropriate to examine what is the
real clinical unmet need for this technology and what are the
remaining obstacles to overcome in making this a clinical
reality. First, currently over 80% of surgical aortic valve
replacement is performed using nonviable heterograft tissue
bioprostheses. Are these sufﬁcient or do we need better
durability that tissue-engineered heart valves potentially
offer? Current surgical heterografts have a durability of 10
to 20 years on the basis of the type of valve used and the
age of the recipient at the time of implantation. It has
been further postulated that the longevity of these valves
could be extended by use of a TAVR valve placed inside the
degenerated surgical tissue bioprosthesis, termed “valve in
valve.” So hypothetically the tandem of a surgical heterograft
followed by a TAVR “valve in valve” could have durability
lasting 20 to 30 years.
Because current TAVR valves are composed of nonliving
heterograft pericardial tissue, concerns have been raised
about possible lessened durability of these valves due to the
mechanical stresses placed on the valve tissue by the crimping
process necessary for catheter-based delivery. Although this
shortened durability has not yet been demonstrated to be a
reality due to the use of these valves in primarily an elderly
population with a life expectancy less than the valve dura-
bility, as TAVR expands into younger populations with
longer life expectancy, a more durable valve would certainly
be attractive. As with degenerated surgically placed tissue
bioprostheses, TAVR valve durability could also conceivably
be extended by a second “valve-in-valve” replacement of a
TAVR implant. So theoretically TAVR valve replacements
could have a durability of 10 to 20 years. With this durability
of current valve technology, it is not clear how much of a need
there is for a tissue-engineered valve.
The ultimate adoption of tissue engineered TAVR
delivered heart valves will depend on a number of factors.
First, clinicians, regulators, and payers are going to have to
be presented with compelling evidence that valve durability
of tissue-engineered heart valves is superior to current gen-
eration surgical and TAVR heterografts. Without a signif-
icant “value added,” clinical adoption will be slow to occur.
Trial design and duration to prove this beneﬁt will be
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1331signiﬁcantly problematic. Second, the technology must be
“user-friendly” in the sense that it must be readily available
in a cost-efﬁcient manner that does not signiﬁcantly disrupt
clinical workﬂow. Unless there is a “burning platform” (i.e.,
easy to implant readily available valve with better durability)
users are unlikely to adopt.
With this study of demonstrating the feasibility of an “off-
the-shelf” tissue-engineered catheter-delivered heart valve,
the authors have gone a long way toward solving this issue.
They have demonstrated the feasibility of off-the-shelf
bioresorbable scaffolds capable of being seeded with autol-
ogous bone marrow mononuclear cells in a 2-h timeframe.
Lastly, and most importantly, do the valves work? Let’s
examine what the authors have been able to demonstrate to
date. The valves can be implanted in the pulmonary position
and function immediately. In another study, the authors have
demonstrated immediate function in the systemic circulation
with the valves implanted in the descending aorta and native
aortic valve (5). They have also been able to demonstrate
immediate competence and host cell repopulation with tissue
remodeling and evidence that stem cells are recruited from
the native circulation. Of some concern, however, is that
although the valves maintain coaptation, they do demon-
strate central incompetence by 24 weeks, presumably due to
tissue remodeling. The authors postulate that this is due to a
ﬂaw in stent design due to the lack of sinuses in the current
stents leading non-physiologic stress on the tissue. They
postulate that this could be rectiﬁed, by a more “natural” stent
design, which includes sinuses. Veriﬁcation of this awaits
further studies, which they are planning.
The journey to a truly autologous tissue-engineered heart
valve has been a long one. The Zurich group has done
pioneering work in this area and is to be congratulated fortheir persistence in overcoming many of the obstacles to
making this a clinical reality. Their translational research in
creating a readily available scaffold in virtually any size with
rapid host cell repopulation and remodeling capabilities is
exciting. We look forward to following their work as they
and others come closer to making their pre-clinical work a
clinical reality.
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